Cencora Inc. (COR)

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. “Ms. Ryerk...

Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can d...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...

COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.

Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S...

Cencora, Inc. (NYSE:COR ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - Preside...

Cencora (COR) came out with quarterly earnings of $4.42 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.80 per share a year ago.